Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolones

Journal of Pharmacology and Experimental Therapeutics

Volumn 328, Issue 2, 2009, Pages 628-634

  Ohta, Kin Ya ^a   Imamura, Yuichiro ^b   Okudaira, Noriko ^b   Atsumi, Ryou ^b   Inoue, Katsuhisa ^a   Yuasa, Hiroaki ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4,4' DIISOTHIOCYANATOSTILBENE 2,2' DISULFONIC ACID; AMMONIUM CHLORIDE; CARRIER PROTEIN; CIMETIDINE; CIPROFLOXACIN; CORTICOSTERONE; ENOXACIN; ESTRONE SULFATE; GATIFLOXACIN; LEVOFLOXACIN; METHOTREXATE; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; NIFLUMIC ACID; NIGERICIN; NORFLOXACIN; PAZUFLOXACIN; PROBENECID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAUROCHOLIC ACID; TOSUFLOXACIN; UNCLASSIFIED DRUG; VERAPAMIL;

ACIDITY; ALKALINITY; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG TRANSPORT; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCYTOSIS;

ANIMALS; ANTIPORTERS; BIOLOGICAL TRANSPORT; CELL LINE; FLUOROQUINOLONES; HYDROGEN-ION CONCENTRATION; IONS; KIDNEY; MEMBRANE TRANSPORT PROTEINS; ORGANIC CATION TRANSPORT PROTEINS; RATS; TOXINS, BIOLOGICAL;

EID: 59649105503     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.142257     Document Type: Article

References (28)

1. Ando T, Kusuhara H, Merino G, Alvarez AI, Schinkel AH, and Sugiyama Y (2007) Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Drug Metab Dispos 35:1873-1879.
2. de Lange EC, Marchand S, van den Berg D, van der Sandt IC, de Boer AG, Delon A, Bouquet S, and Couet W (2000) In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. Eur J Pharm Sci 12:85-93.
3. Emmerson AM and Jones AM (2003) The quinolones: decades of development and use. J Antimicrob Chemother 51:13-20.
4. 14C] T-3761 in rats and mice. Jpn J Antibiot 48:671-685.
5. Huls M, Brown CD, Windass AS, Sayer R, van den Heuvel JJ, Heemskerk S, Russel FG, and Masereeuw R (2008) The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int 73:220-225.
6. Lowes S and Simmons NL (2002) Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 135:1263-1275.
7. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
8. 14C-T-3262) in rats and mice. Jpn J Antibiot 42:854-867.
9. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, and Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464.
10. Merino G, Alvarez AI, Pulido MM, Molina AJ, Schinkel AH, and Prieto JG (2006) Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos 34:690-695.
11. Miyamae S, Ueda O, Yoshimura F, Hwang J, Tanaka Y, and Nikaido H (2001) A MATE family multidrug efflux transporter pumps out fluoroquinolones in Bacteroides thetaiotaomicron. Antimicrob Agents Chemother 45:3341-3346.
12. Morita Y, Kodama K, Shiota S, Mine T, Kataoka A, Mizushima T, and Tsuchiya T (1998) Norm, a putative multidrug efflux protein, of Vibrio parahaemolyticus and its homolog in Escherichia coli. Antimicrob Agents Chemother 42:1778-1782.
13. Nakamura S, Kurobe N, Kashimoto S, Ohue T, Takase Y, and Shimizu M (1983) Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. Antimicrob Agents Chemother 24:54-60.
14. Naruhashi K, Tamai I, Inoue N, Muraoka H, Sai Y, Suzuki N, and Tsuji A (2002) Involvement of multidrug resistance-associated protein 2 in intestinal secretion of grepafloxacin in rats. Antimicrob Agents Chemother 46:344-349.
15. Neuman M (1988) Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet 14:96-121.
16. Nouaille-Degorce B, Veau C, Dautrey S, Tod M, Laouari D, Carbon C, and Farinotti R (1998) Influence of renal failure on ciprofloxacin pharmacokinetics in rats. Antimicrob Agents Chemother 42:289-292.
17. + antiporter in the kidney. Drug Metab Dispos 34:1868-1874.
18. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, and Moriyama Y (2005) A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A 102:17923-17928.
19. Rouquette-Loughlin C, Dunham SA, Kuhn M, Balthazar JT, and Shafer WM (2003) The norm efflux pump of Neisseria gonorrhoeae and Neisseria meningitidis recognizes antimicrobial cationic compounds. J Bacteriol 185:1101-1106.
20. Sarkadi B, Homolya L, Szakács G, and Váradi A (2006) Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 86:1179-1236.
21. Sasabe H, Tsuji A, and Sugiyama Y (1998) Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats. J Pharmacol Exp Ther 284:1033-1039.
22. Sörgel F and Kinzig M (1993a) Pharmacokinetics of gyrase inhibitors: I. Basic chemistry and gastrointestinal disposition. Am J Med 94:44S-55S.
23. Sörgel F and Kinzig M (1993b) Pharmacokinetics of gyrase inhibitors: II. Renal and hepatic elimination pathways and drug interactions. Am J Med 94:56S-69S.
24. +-organic cation antiporters. Biochem Pharmacol 74:359-371.
25. +/organic cation antiporter MATE1. Am J Physiol Renal Physiol 292:F593-F598.
26. Turnidge J (1999) Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 58:29-36.
27. Vanwert AL, Srimaroeng C, and Sweet DH (2008) Organic anion transporter 3 (Oat3/Slc22a8) interacts with carboxyfluoroquinolones and deletion increases systemic exposure to ciprofloxacin. Mol Pharmacol 74:122-131.
28. Wagenlehner FM and Naber KG (2003) Prostatitis: the role of antibiotic treatment. World J Urol 21:105-108.